Related Experiment Video

Updated: Aug 11, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

[Adverse reactions and immune response to Heberbiovac-HB vaccine administered to infants simultaneously with DPT and

M Díaz González1, L Rodríguez Lay, A U López-Chávez

  • 1Instituto de Medicina Tropical Pedro Kourí, Ciudad de La Habana, Cuba.

Revista Cubana De Medicina Tropical
|January 1, 1997
PubMed

Insights

The Cuban Heberbiovac-HB vaccine shows acceptable safety and strong immune response in infants. Co-administration with other vaccines did not interfere with its effectiveness.

Area of Science:

  • Vaccinology
  • Immunology
  • Pediatrics

Background:

  • Hepatitis B remains a significant global health concern.
  • Effective vaccination strategies are crucial for preventing Hepatitis B virus transmission.
  • The Cuban recombinant yeast-derived hepatitis B vaccine (Heberbiovac-HB) is a key intervention.

Purpose of the Study:

  • To evaluate the reactogenicity and immunogenicity of Heberbiovac-HB in infants.
  • To assess the safety profile of Heberbiovac-HB.
  • To determine potential immunological interference when co-administered with other vaccines.

Main Methods:

  • Two groups of 3-month-old infants received Heberbiovac-HB (10 micrograms) on different schedules (0, 1, 6 months or 0, 1, 2, 12 months).
  • Vaccinations were co-administered with DPT and anti-meningococcal vaccines.
  • Reactogenicity (fever, erythema, induration) and immunogenicity (anti-HBs antibody titres) were monitored.

Main Results:

  • Observed reactions were mild and comparable to existing studies.
  • High percentages of infants in both groups achieved anti-HBs antibody titres exceeding 100 UI/L.
  • No evidence of immunological interference from co-administered vaccines was found.

Conclusions:

  • Heberbiovac-HB demonstrates acceptable reactogenicity in infants.
  • The vaccine elicits a robust immunogenic response.
  • Co-administration with DPT and anti-meningococcal vaccines does not compromise Heberbiovac-HB efficacy.

More Related Videos

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...